Effect of Hericium Erinaceus on Clinical Patients With Hearing Impairment

Overview

This study aims to investigate the effect of Hericium Erinaceus on clinical patients with hearing impairment and possible mechanisms. Subjects with hearing impairment will be enrolled and randomly divided into experimental or control group supplemented with Hericium Erinaceus (430 mg/kg/day) or placebo, respectively for eight months. Basic characteristics will be evaluated at baseline by questionnaire. The hearing, liver and kidney functions, and neurotrophic factors will be examined at baseline, 4th month and 8th month.

Full Title of Study: “Effect of Hericium Erinaceus on Clinical Patients With Hearing Impairment and Possible Mechanisms”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Supportive Care
    • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: January 17, 2019

Detailed Description

This study aims to investigate the effect of Hericium Erinaceus on clinical patients with hearing impairment and possible mechanisms. Subjects with hearing impairment will be enrolled. Inclusion criteria were 50 to 79 years old with symmetric sensorineural hearing loss, subjective sensorineural tinnitus, and all frequencies differed of ears less than 15 dB. Exclusion conditions were patients with abnormal liver and kidney function, normal hearing, severe and very severe hearing loss, no tinnitus or non-subjective sensorineural tinnitus, moderate or more cognitive impairment, patients unable to understand the details of this study or patients unable to co-examine, history of alcohol or drug abuse, history of high ambient noise exposure, bone tone air gap of pure tone hearing threshold greater than 10 dB, and audiogram 4 kHz air conduction threshold greater than 8 kHz, 20 dB airway threshold, hearing impairment before age 30, and inability to understand the details of this study. Participants will randomly divide into experimental or control group supplemented with Hericium Erinaceus (430 mg/kg/day) or placebo, respectively for eight months by a prospective, randomized, double-blind approach. Basic characteristics will be evaluated at baseline by questionnaire. The status of hearing, and CBC, GOT, GPT, BUN, Creatinine, NGF and BDNF expressions in blood will be examined at baseline, 4th month and 8th month.

Interventions

  • Dietary Supplement: Hericium honey bolus
    • The subjects of the experimental group will be supplemented with Hericium Erinaceus honey bolus(430 mg/kg/day) for eight months.
  • Dietary Supplement: Placebo honey bolus
    • The subjects of the control group will be supplemented with Placebo honey bolus(8 bolus/ day) for 8 months.

Arms, Groups and Cohorts

  • Experimental: Hericium honey bolus
    • Dosage form: honey bolus Dosage : Hericium erinaceus mycelium 250mg/day Frequency: 8 bolus/ day Duration: 8 months
  • Placebo Comparator: Control group
    • Dosage form: Placebo honey bolus Dosage : maize starch Frequency: 8 bolus/ day Duration: 8 months

Clinical Trial Outcome Measures

Primary Measures

  • 1.Change of Tinnitus status evaluates by Tinnitus handicap inventory (THI)
    • Time Frame: Baseline, 4th month and 8th month
    • The status of tinnitus will be evaluated by Tinnitus handicap inventory (THI). THI is divided into three categories, including the functional (12 questions), emotional (8 questions), and catastrophic (5 questions) subscore. A total of 25 questions are used. The answer will be divided into three levels (will, sometimes, will not), and be scored into 4, 2 and 0 point, respectively. The subscore of functional (12 questions), emotional (8 questions), and catastrophic (5 questions) are 48, 32, and 20, respectively. The highest total score is 100 points. The higher the score, the more the tinnitus is. The difference of score will be compared from the baseline with 4th and 8th month.
  • Change of Tinnitus severity evaluates by visual analog scale (VAS)
    • Time Frame: Baseline, 4th month and 8th month
    • The severity of tinnitus will be scored with a visual analog scale (VAS) from point 0 to point 10 by subject. The difference of score will be compared from the baseline with 4th and 8th month.
  • Changes of hearing obstacle average measure by Pure Tone Audiometry(PTA)
    • Time Frame: Baseline, 4th month and 8th month
    • Pure tone threshold of subjects will be measured by Pure Tone Audiometry (PTA) to evaluate the changes from baseline ageing hearing obstacle average (dB HL) with 4th and 8th month.
  • Changes of speech recognizing measure by Speech Audiometry.
    • Time Frame: Baseline, 4th month and 8th month
    • The Speech Audiometry is used to evaluate the changes of baseline speech recognizing (dB HL) and speech speech recognition rate(%) with 4th and 8th month.
  • Changes of NGF and BDNF levels of blood investigate by enzyme-linked immunosorbent assay (ELISA)
    • Time Frame: Baseline, 4th month and 8th month
    • The NGF and BDNF levels of blood will be analyzed by enzyme-linked immunosorbent assay (ELISA) to detect the presence of NGF and BDNF. The NGF and BDN levels will be quantitative by the optical density (OD) of the sample comparing to a standard curve, which is a serial dilution of a known-concentration solution of the target molecule. The difference of NGF and BDNF levels will be compared from the baseline with 4th and 8th month.

Participating in This Clinical Trial

Inclusion Criteria

  • Patients aged 50 to 79 years old with symmetric sensorineural hearing loss, subjective sensorineural tinnitus, and all frequencies differed of ears less than 15 dB.

Exclusion Criteria

  • Patients with abnormal liver and kidney function, normal hearing, severe and very severe hearing loss, no tinnitus or non-subjective sensorineural tinnitus, moderate or more cognitive impairment , patients unable to understand the details of this study or patients unable to co-examine, history of alcohol or drug abuse, history of high ambient noise exposure, bone tone air gap of pure tone hearing threshold greater than 10 dB, and audiogram 4 kHz air conduction threshold greater than 8 kHz, 20 dB airway threshold, hearing impairment before age 30, and inability to understand the details of this study.

Gender Eligibility: All

Minimum Age: 50 Years

Maximum Age: 79 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Providence University, Taiwan
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Yin-Ching Chan, Study Chair, Providence University
  • Overall Contact(s)
    • Yin-Ching Chan, PhD, 886921376777, ycchan@pu.edu.tw

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.